Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Brian Tomlinson, Paul Chan & Christopher Wai Kei Lam. (2020) Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. Expert Review of Endocrinology & Metabolism 15:3, pages 147-157.
Read now
Read now
María Molina Vega, Araceli Muñoz-Garach & Francisco J. Tinahones. (2018) Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 14:2, pages 207-217.
Read now
Read now
Niels B. Dalsgaard, Andreas Brønden, Tina Vilsbøll & Filip K. Knop. (2017) Cardiovascular safety and benefits of GLP-1 receptor agonists. Expert Opinion on Drug Safety 16:3, pages 351-363.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Liraglutide for weight management: benefits and risks. Current Medical Research and Opinion 33:3, pages 537-539.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 211-223.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1267-1271.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs 25:10, pages 1167-1179.
Read now
Read now
Articles from other publishers (30)
Cristina Bouzas, Rosario Pastor, Silvia Garcia, Margalida Monserrat-Mesquida, Miguel Ángel Martínez-González, Jordi Salas-Salvadó, Dolores Corella, Albert Goday, J. Alfredo Martínez, Ángel M. Alonso-Gómez, Olga Fernández-Barceló, Jesús Vioque, Dora Romaguera, José Lopez-Miranda, Ramón Estruch, Francisco J. Tinahones, José Lapetra, Lluís Serra-Majem, Blanca Riquelme-Gallego, Vicente Martín-Sánchez, Xavier Pintó, Miguel Delgado-Rodriguez, Pilar Matía, Josep Vidal, Jersy-Jair Cardenas-Salas, Lidia Daimiel, Emilio Ros, Estefanía Toledo, Josep M. Manzanares, Inmaculada Gonzalez-Monge, Miguel-Ángel Muñoz, Diego Martinez-Urbistondo, Lucas Tojal-Sierra, Carlos Muñoz-Bravo, Salvador Miralles-Gisbert, Marian Martin, Antonio García-Ríos, Sara Castro-Barquero, José Carlos Fernández-García, José Manuel Santos-Lozano, F. Javier Basterra-Gortari, Liliana Gutiérrez-Carrasquilla, Patricia Guillem-Saiz, Alba Satorres, Itziar Abete, Carolina Sorto-Sanchez, Javier Díez-Espino, Nancy Babio, Montse Fitó & Josep A. Tur. (2023) Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. Biomedicine & Pharmacotherapy 161, pages 114561.
Crossref
Crossref
Baisen Chen, Zhiqiang Shi, Yechun Wang, Minting Chen, Chunfang Yang, Hui Cui, Tao Su & Hiu Yee Kwan. (2022) Discovery of a novel anti-obesity meroterpenoid agent targeted subcutaneous adipose tissue. Phytomedicine 106, pages 154396.
Crossref
Crossref
Mohamed Sayed Zaazouee, Aboalmagd Hamdallah, Sara Kamel Helmy, Elfatih A. Hasabo, Ahmed Kamal Sayed, Mohamed Ibrahim Gbreel, Aya Abd Elmegeed, Hala Aladwan, Alaa Ahmed Elshanbary, Walid Abdel-Aziz, Israa Mohamed Elshahawy, Shehab Rabie, Sherouk Elkady, Ahmed Said Ali, Khaled Mohamed Ragab & Anas Zakarya Nourelden. (2022) Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:6, pages 102511.
Crossref
Crossref
Xiaoliang Sun, Ziyuan Zhang, Meiyan Liu, Peng Zhang, Liqin Nie, Yuqing Liu, Ye Chen, Fengjiao Xu, Zhonghua Liu & Youlin Zeng. (2022) Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives. Biomedicine & Pharmacotherapy 148, pages 112722.
Crossref
Crossref
Jinhua Zhang, Yuanzhen Dong, Dianwen Ju & Jun Feng. (2021) Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates. Bioorganic & Medicinal Chemistry 44, pages 116291.
Crossref
Crossref
Antonella Grigoletto, Tommaso Tedeschini, Elena Canato & Gianfranco Pasut. (2020) The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules. WIREs Nanomedicine and Nanobiotechnology 13:3.
Crossref
Crossref
Tine A. Bækdal, Morten Donsmark, Marie‐Louise Hartoft‐Nielsen, Flemming L. Søndergaard & Alyson Connor. (2021) Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study. Clinical Pharmacology in Drug Development 10:5, pages 453-462.
Crossref
Crossref
Jiang Liu, Jianlin Han, Kunisuke Izawa, Tatsunori Sato, Sarah White, Nicholas A. Meanwell & Vadim A. Soloshonok. (2020) Cyclic tailor-made amino acids in the design of modern pharmaceuticals. European Journal of Medicinal Chemistry 208, pages 112736.
Crossref
Crossref
Caroline Tsao, Peng Zhang, Zhefan Yuan, Dianyu Dong, Kan Wu, Liqian Niu, Patrick McMullen, Sijin Luozhong, Hsiang-Chieh Hung, Yu-Hong Cheng & Shaoyi Jiang. (2020) Zwitterionic Polymer Conjugated Glucagon-like Peptide-1 for Prolonged Glycemic Control. Bioconjugate Chemistry 31:7, pages 1812-1819.
Crossref
Crossref
Amit Gupta, Tapan Behl & Monika Sachdeva. (2020) Key milestones in the diabetes research: A comprehensive update. Obesity Medicine 17, pages 100183.
Crossref
Crossref
Hannah Gardner & Osama Hamdy. (2020) Oral GLP1 Analog: Where Does the Tide Go?. Clinical Medicine Insights: Endocrinology and Diabetes 13, pages 117955142098413.
Crossref
Crossref
Samuel Zalipsky & Gianfranco Pasut. 2020. Polymer-Protein Conjugates. Polymer-Protein Conjugates
3
22
.
María L. López-Rodríguez, Bellinda Benhamú & Henar Vázquez-Villa. 2020. GPCRs. GPCRs
195
241
.
Nikolaj Nerup, Rikard Ambrus, Joanna Lindhe, Michael P. Achiam, Palle B. Jeppesen & Lars B. Svendsen. (2019) The effect of glucagon‐like peptide‐1 and glucagon‐like peptide‐2 on microcirculation: A systematic review. Microcirculation 26:3, pages e12367.
Crossref
Crossref
Tejashree Redij, Rajan Chaudhari, Zhiyu Li, Xianxin Hua & Zhijun Li. (2019) Structural Modeling and in Silico Screening of Potential Small-Molecule Allosteric Agonists of a Glucagon-like Peptide 1 Receptor. ACS Omega 4:1, pages 961-970.
Crossref
Crossref
Rajesh Gupta, Dan C. Nguyen, Michael D. Schaid, Xia Lei, Appakalai N. Balamurugan, G. William Wong, Jeong-a Kim, James E. Koltes, Michelle E. Kimple & Sushant Bhatnagar. (2018) Complement 1q-like-3 protein inhibits insulin secretion from pancreatic β-cells via the cell adhesion G protein–coupled receptor BAI3. Journal of Biological Chemistry 293:47, pages 18086-18098.
Crossref
Crossref
Rosa Bretón‐Romero, Robert M. Weisbrod, Bihua Feng, Monika Holbrook, Darae Ko, Mary M. Stathos, Ji‐Yao Zhang, Jessica L. Fetterman & Naomi M. Hamburg. (2018) Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus. Journal of the American Heart Association 7:18.
Crossref
Crossref
Alberto Oddo, Sofia Mortensen, Henning Thøgersen, Leonardo De Maria, Stephanie Hennen, James N. McGuire, Jacob Kofoed, Lars Linderoth & Steffen Reedtz-Runge. (2018) α-Helix or β-Turn? An Investigation into N-Terminally Constrained Analogues of Glucagon-like Peptide 1 (GLP-1) and Exendin-4. Biochemistry 57:28, pages 4148-4154.
Crossref
Crossref
Jia Ying Cheang & Peter M. Moyle. (2018) Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes. ChemMedChem 13:7, pages 662-671.
Crossref
Crossref
Jing Han, Yingying Fei, Feng Zhou, Xinyu Chen, Ying Zhang, Lin Liu & Junjie Fu. (2018)
Xenopus
-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities
. British Journal of Pharmacology 175:3, pages 544-557.
Crossref
Crossref
Annie Hasib, Ming T. Ng, Dawood Khan, Victor A. Gault, Peter R. Flatt & Nigel Irwin. (2018) A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice. Peptides 100, pages 202-211.
Crossref
Crossref
Ayumu Niida, Yoko Kanematsu-Yamaki, Tomoko Asakawa, Yoshimasa Ishimura, Hisashi Fujita, Kouta Matsumiya, Naoki Nishizawa, Yusuke Adachi, Taisuke Mochida, Kazue Tsuchimori, Mariko Yoneyama-Hirozane, Junichi Sakamoto, Hideki Hirabayashi, Hideo Fukui, Shiro Takekawa & Taiji Asami. (2018) Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives. Bioorganic & Medicinal Chemistry 26:3, pages 566-572.
Crossref
Crossref
Jing Han, Yingying Fei, Feng Zhou, Xinyu Chen, Weiwei Zheng & Junjie Fu. (2017)
Micellar Nanomedicine of Novel Fatty Acid Modified
Xenopus
Glucagon-like Peptide-1: Improved Physicochemical Characteristics and Therapeutic Utilities for Type 2 Diabetes
. Molecular Pharmaceutics 14:11, pages 3954-3967.
Crossref
Crossref
Dominic N. McBrayer & Yftah Tal-Gan. (2017) Recent Advances in GLP-1 Receptor Agonists for Use in Diabetes Mellitus. Drug Development Research 78:6, pages 292-299.
Crossref
Crossref
Ivan N. Tyurenkov, Denis V. Kurkin, Dmitry A. Bakulin, Elena V. Volotova, Mikhail A. Chafeev, Alexey V. Smirnov & Evgeny I. Morkovin. (2017) ZB-16, a Novel GPR119 Agonist, Relieves the Severity of Streptozotocin–Nicotinamide-Induced Diabetes in Rats. Frontiers in Endocrinology 8.
Crossref
Crossref
Sergei Pechenov, Himanshu Bhattacharjee, Daniel Yin, Sachin Mittal & J. Anand Subramony. (2017) Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Advanced Drug Delivery Reviews 112, pages 106-122.
Crossref
Crossref
Denise Wootten, Laurence J. Miller, Cassandra Koole, Arthur Christopoulos & Patrick M. Sexton. (2016) Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. Chemical Reviews 117:1, pages 111-138.
Crossref
Crossref
A. Palani, Y.-Y. Zhou, M. Halleck & P. Carrington. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
481
490
.
Hitesh Soni. (2016) Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity. Medical Hypotheses 95, pages 5-9.
Crossref
Crossref
Bogdan-Mircea Mihai, Cristina Mihaela Lăcătuşu, Elena-Daniela Grigorescu & Gina Eosefina Botnariu. (2015) Innovative Therapies in Type 2 Diabetes: The Dream of the Future. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 22:4.
Crossref
Crossref